Retinal diseases represent a growing challenge in public health, affecting millions and leading to significant vision impairment or blindness if left unchecked. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO) damage the retina—the light-sensitive tissue at the back of the eye responsible for transmitting visual signals to the brain. AMD progressively destroys central vision, crucial for reading and recognizing faces. DR, a complication of diabetes mellitus, involves blood vessel abnormalities in the retina that can cause leakage or abnormal growth. DME occurs when DR leads to swelling in the macula, the central retina area. RVO happens when blocked retinal veins cause swelling and hemorrhages, threatening vision.
These diseases not only impair quality of life but also impose a heavy burden on individuals, families, and the healthcare system. Vision loss correlates with increased risks of falls, depression, and dependency, particularly among older adults. Early detection through comprehensive dilated eye exams remains key, yet access varies widely across the United States.
A Groundbreaking Meta-Analysis on US Prevalence
A comprehensive meta-analysis published in JAMA Ophthalmology on March 19, 2026, provides the most updated estimates of retinal disease burden in the US as of 2022. Led by researchers including T.Y. Alvin Liu, MD, from institutions like Duke University Eye Center, University of California San Francisco, and the Institute for Health Metrics and Evaluation at the University of Washington, the study synthesizes data from the National Health and Nutrition Examination Survey (NHANES), Medicare claims, commercial insurance databases, and population-based studies.
Using Bayesian meta-regression, the team generated age-standardized prevalence rates per 100,000 people, revealing nearly 34 million Americans affected. This work underscores the academic rigor needed to map disease patterns and guide policy, highlighting collaborations between universities and health organizations.
Robust Methodology Driving Reliable Insights
The study's strength lies in its multifaceted data integration. NHANES provided population-representative surveys from 2005-2008 and 2017-2020, capturing undiagnosed cases. Medicare fee-for-service claims (2017-2019) focused on older adults, while IBM MarketScan (2016) covered working-age commercially insured individuals. The CDC's Vision and Eye Health Surveillance System (VEHSS) supplemented with state-level granularity. Analyses adjusted for age using the 2010 US Census pyramid, ensuring comparability.
Prevalence definitions were precise: total AMD for ages 40+, DR and DME among diabetics across ages (stratified by vision-threatening), and RVO (branch or central) for ages 18+. Uncertainty intervals (95% UI) accounted for variability, making estimates robust for planning.
National Prevalence: A Stark Snapshot
Age-standardized rates paint a sobering picture: AMD at 5,677 (95% UI: 4,513-7,374) per 100,000, affecting roughly 21.9 million crudely. DR: 2,710 (2,112-3,647), impacting 10 million diabetics. DME: 317 (243-505), about 1.1 million. RVO: 214 (168-409), nearly 900,000. These translate to profound vision loss risks, with DR and DME often progressing silently in underserved groups.
| Condition | Prevalence per 100,000 (2022) | Crude Affected (millions) |
|---|---|---|
| AMD | 5,677 | 21.9 |
| DR | 2,710 | 10.0 |
| DME | 317 | 1.1 |
| RVO | 214 | 0.9 |
Sex Disparities: Men at Higher Risk
Males consistently showed elevated prevalence across all conditions. For AMD, 6,104 vs. 5,312 per 100,000 in females; DR: 3,265 vs. 2,211; DME: 356 vs. 281; RVO: 243 vs. 191. This may stem from higher diabetes rates in men, occupational exposures, or behavioral factors like smoking. Addressing male-specific risks through targeted screenings could mitigate progression.
Racial and Ethnic Disparities: Patterns of Inequity
Racial patterns reveal inequities tied to social determinants. Whites faced 1.7-fold higher AMD (6,038 per 100,000) than Blacks (3,534) and 2-fold RVO than Hispanics. Conversely, Blacks had over 2-fold DR (4,462 vs. 2,148 Whites) and 4.6-fold DME (712 vs. 155). Hispanics showed 1.8-fold DR (3,830) and 3.7-fold DME (578) vs. Whites. These align with diabetes prevalence disparities—higher in minorities—and barriers like access.Full study details here.
Photo by Denis Sebastian Tamas on Unsplash
- Black patients: 20-60% less likely to receive anti-VEGF for DME historically.
- Hispanic underdiagnosis due to language, insurance gaps.
Regional Variations: Hotspots and deserts
State-level differences expose care deserts. AMD peaked in Rhode Island (7,214 per 100,000), lowest DC (3,497). DR highest Mississippi (3,607), lowest Montana (1,654). DME: DC (504) vs. Vermont (126). RVO: Rhode Island (273) vs. Hawaii (157). Patient-to-specialist ratios extreme: Wyoming 6,345 for AMD, Mississippi 3,015 for DR. South and rural areas lag, correlating with poverty, diabetes belts.
California boasts 918 retina specialists; Wyoming just 3, straining telehealth needs.
Economic Burden: Billions in Costs
Retinal diseases drive massive expenses. Annual payer costs: AMD $13.4B, DR $6.2B, DME $4.4B, RVO $6.4B. Broader vision loss totals $134B yearly—$98.7B direct medical/nursing, $35.5B indirect productivity. IRDs alone exceed $60% wellbeing costs. Disparities amplify via delayed care, higher complications.CDC economic data.
Root Causes: Intersecting Factors
Diabetes epidemic fuels DR/DME, disproportionately hitting minorities (13.4% Black vs. 7.4% non-Hispanic White adults). Aging drives AMD (65+ peak). Social determinants—poverty, food insecurity, transport—exacerbate in South, Appalachia. Genetic predispositions, hypertension interplay.
Treatment Landscape and Gaps
Anti-VEGF injections (e.g., aflibercept, ranibizumab) stabilize AMD/DR/DME/RVO, but require frequent visits. Laser, steroids adjunct. Yet, Black patients 20-30% less treated for DME. Rural access poor; uninsured 2x vision loss risk.
Solutions: Bridging the Equity Gap
Telemedicine retinal imaging boosts screening 117-119% in diabetics. Community programs, mobile units target high-burden areas. Policy: expand Medicaid eye coverage, train diverse providers. AI diagnostics aid underserved.
- Annual screenings for diabetics.
- Social prescribing for SDOH.
- Health education culturally tailored.
Universities like Duke lead trials enhancing diversity.
Academic Research's Pivotal Role
Higher education drives progress. UW IHME models, Duke/UCSF clinical insights fuel equity research. Funding NIH/NEI trials diverse cohorts. Programs train minority ophthalmologists, vital as field 80% White.
Photo by Kier in Sight Archives on Unsplash
Looking Ahead: Optimistic Outlook
With rising awareness, interventions could halve blindness by 2030. Gene therapies, sustained-release implants promise less burden. Equitable allocation per this study—prioritize Mississippi DR, RI AMD—transforms care. Collaborative research positions US leadership.
